News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Daily News Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC Michael O'Riordan June 25, 2025
News Daily News Majority of US Adults Have High Long-term Risk of CVD: NHANES Michael O'Riordan June 13, 2025
News Conference News European Congress on Obesity 2025 App-Based Support Aids Weight Loss With Semaglutide, Studies Show Michael O'Riordan May 13, 2025
News Daily News Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds Michael O'Riordan April 25, 2025
News Daily News Weekend Warriors Also See Mortality Benefits With Exercise Michael O'Riordan April 10, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025
News Daily News CVD Hospitalization in Older Adults Higher in US Than in Denmark Michael O'Riordan February 07, 2025
News Daily News US Football Fans Are Flooded With Ads for Unhealthy Foods Michael O'Riordan January 30, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025